去勢抵抗性前立腺がん　薬物療法UPDATE

出版社： 先端医学社
著者：
発行日： 2015-01-25
分野： 臨床医学：一般  >  癌/腫瘍一般
ISBN： 9784865500462
電子書籍版： 2015-01-25 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

4,400 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

2,200 円(税込)

購入する

目次

  • 去勢抵抗性前立腺がん　薬物療法UPDATE

    ―目次―

    PART 1　CRPCの病態を把握する！
    1 CRPCの病態，定義と概念および治療の変遷　　
    2 CRPCの去勢抵抗性獲得の分子メカニズム

    PART 2　CRPC治療薬のプロファイルを整理する！
    1 ドセタキセル
    2 アビラテロン
    3 エンザルタミド
    4 カバジタキセル
    ポイント解説 各薬剤の特徴を整理する

    PART3　CRPC 治療薬はこう使う！
    　　　　─適応となる患者像と処方の実際─
    1 ドセタキセル
    2 アビラテロン
    3 エンザルタミド
    4 カバジタキセル
    ポイント解説 処方における留意点　

    PART 4 想定すべき副作用とは？ 適切な対応とは？
    1 ドセタキセル
    2 アビラテロン
    3 エンザルタミド
    4 カバジタキセル
    ポイント解説 副作用のマネジメント

    PART 5 CRPCの臨床マネジメントの展望と今後の可能性
    1 CRPC治療薬における至適シークエンスの展望
    2 高齢者におけるCRPCに対する薬物治療の考え方
    3 CRPC治療におけるQOL?ADL管理の実際
    4 ホルモンナイーブ前立腺がんに対する新規治療薬の可能性
    5 CRPC治療薬と集学的治療
    6 骨転移前立腺がんと新規CRPC治療薬（radium-223,cabozantinib）

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

PART 1 CRPCの病態を把握する !

P.17 掲載の参考文献
1) Huggins C, Hodges CV : Studies on prostatic cancer : I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1 : 293-297, 1941
 
2) Tannock IF, de Wit R, Berry WR et al : Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 : 1502-1512, 2004
 
3) Scher HI, Steinek G, Kelly WK : Hormonerefractory (D3) prostate cancer : refining the concept. Urology 46 : 142-148, 1995
 
4) Scher HI, Buchanan G, Gerald W et al : Targeting the androgen receptor : improving outcomes for castration-resistant prostate cancer. Endocr Relat Cancer 11 : 459-476, 2004
PubMed
5) 前立腺癌取扱い規約 (第4版). 日本泌尿器科学会, 日本病理学会, 日本医学放射線学会編, 金原出版, 東京, 2010
 
6) European Association of Urology : Guidelines on Prostate Cancer. 2013 (http://www.uroweb.org/gls/pdf/09_Prostate_Cancer_L2.pdf)
 
7) European Association of Urology : Guidelines on Prostate Cancer. 2014 (http://www.uroweb.org/gls/pdf/09%20Prostate％20Cancer_LRLV2.pdf)
 
8) 鈴木和浩 : CRPCの定義と発症メカニズム. 泌尿器外科 24 : 1707-1714, 2011
Medical*Online
9) Antonarakis ES, Lu C, Wang H et al : AR-V7 and resistarlce to enzalutamide and abiraterone in prostate cancer. N Engl J Med 371 : 1028-1038, 2014
PubMed
10) Nelson PS : Molecular states underlying androgen receptor activation : a framework for therapeutic targeting androgen signaling in prostate cancer. J Clin Oncol 30 : 644-646, 2012
PubMed
11) 鈴木和浩 : 進化する去勢抵抗性前立腺癌の治療戦略 Urology Today 21 : 4-8, 2014
 
12) William Oh : Castration-Resistant Prostate Cancer : The Place of Novel Agents Focused on the Androgen Axis. 2013 ASCO Annual Meeting, 2013
 
13) Miyamoto S, Ito K, Miyakubo M et al : Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy. Prostate Cancer Prostatic Dis 15 : 75-86, 2012
PubMed
14) Naito S, Tsukamoto T, Koga H et al : Docetaxel plus prednisone for the treatment of metastatic hormone-refractory prostate cancer : a multicenter Phase II trial in Japan. Jpn J Clin Oncol 38 : 365-372, 2008
 
15) Miyake H, Sakai I, Terakawa T et al : Oncological outcome of docetaxel-based chemotherapy for Japanese men with metastatic castration-resistant prostate cancer. Urol Oncol 31 : 733-738, 2013
PubMed
16) Akaza H, Hinotsu S, Usami M et al : Combined androgen blockade with bicalutamide for advanced prostate cancer : long-term follow-up of a phase 3, double-blind, randomized study for survival. Cancer 115 : 3437-3445, 2009
PubMed
17) Suzuki H, Okihara K, Miyake H et al : Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after intial maximum androgen blockade. J Urol 180 : 921-927, 2008
 
18) Sartor AO, Tangen CM, Hussain MH et al : Antiandrogen withdrawal in castration-refractory prostate cancer. Cancer 112 : 2393-2400, 2008
PubMed
19) Kamiya N, Suzuki H, Nishimura K et al : Development of nomogram to non-steroidal antiandrogen sequential alteration in Prostate cancer for predictive model. Jpn J Clin Oncol 44 : 263-269, 2014
 
20) Cookson MS, Roth BJ, Dahm P et al : Castration-resistant prostate cancer : AUA Guideline. J Urol 190 : 429-438, 2013
PubMed
21) Mohler JL, Kantoff PW, Armstrong AJ et al : Prostate cancer, version 1.2014. J Natl Canc Netw 11 : 1471-1479, 2013
PubMed
P.26 掲載の参考文献
1) Guo Z, Qiu Y : A new trick of an old molecule : androgen receptor splice variants taking the stage?! Int/Biol Sci 7 : 815-822, 2011
 
2) Koochekpour S : Androgen receptor signaling and mutations in prostate cancer. Asian J Androl 12 : 639-657, 2010
PubMed
3) Ferraldeschi R, Welti J, Luo J et al : Targeting the androgen receptor pathway in castration-resistant prostate cancer : progresses and prospects. Oncogene, 2014 [Epub ahead of print]
 
4) Shafi AA, Yen AE, Weigel NL : Androgen receptors in hormone-dependent and castration-resistant prostate cancer. Pharmacol Ther 140 : 223-238, 2013
PubMed
5) Wu D, Sunkel B, Chen Z et al : Three-tiered role of the pioneer factor GATA2 ill promoting androgen-deperldent gene expression in Prostate cancer. Nucleic Acids Res 42 : 3607-3622, 2014
 
6) Augello MA, Hickey TE, Knudsen KE : FOXA1 : master of steroid receptor function in cancer. EMBO J 30 : 3885-3894, 2011
PubMed
7) Yuan X, Cai C, Chen S et al : Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis. Oncogene 33 : 2815-2825, 2014
PubMed
8) Beltran H, Yelensky R, Frampton GM et al : Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Eur Urol 63 : 920-926, 2013
PubMed
9) Korpal M, Korn JM, Gao X etal : An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). Cancer Discov 3 : 1030-1043, 2013
PubMed
10) Suzuki H, Akakura K, Komiya A et al : Codon 877 mutation in the androgen receptor gene in advanced prostate cancer : relation to antiandrogen withdrawal syndrome. Prostate 29 : 153-158, 1996
PubMed
11) Taylor BS. Schultz N, Hieronymus H et al : Integrative genomic profiling of human prostate cancer. Cancer Cell 18 : 11-22, 2010
PubMed
12) Linja MJ, Savinainen KJ, Saramaki OR et al : Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 61 : 3550-3555, 2001
 
13) Shaffer DR, Leversha MA, Danila DC et al : Circulating tumor cell analysis in patients with progresslve castratlon-reslstant prostate cancer. Clin Cancer Res 13 : 2023-2029, 2007
PubMed
14) Chen Y, Sawyers CL, Scher HI : Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol 8 : 440-448, 2008
PubMed
15) Chen CD, Welsbie DS, Tran C et al : Molecular determinants of resistance to antiandrogen therapy. Nat Med 10 : 33-39, 2004
PubMed
16) Palmberg C, Koivisto P, Kakkola L et al : Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer. J Urol 164 : 1992-1995, 2000
PubMed
17) Guo Z, Yang X, Sun F et al : A novel androgen receptor splice variant is し1p-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res 69 : 2305-2313, 2009
 
18) Hu R, Lu C, Mostaghel EA et al : Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res 72 : 3457-3462, 2012
PubMed
19) Yu Z, Chen S, Sowalsky AG et al : Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer. Clin Cancer Res 20 : 1590-1600, 2014
 
20) Efstathiou E, Titus M, Wen S et al : Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer. Eur Urol, 2014 [Epub ahead of print]
 
21) Sun S, Sprenger CC, Vessella RL et al : Castration resistance in human prostate cancer is conferred by a freqし1ently occurring androgen receptor splice variant. J Clin Invest 120 : 2715-2730, 2010
 
22) Nyquist MD, Li Y, Hwang TH et al : TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prosate cancer. Proc Natl Acad Sci U S A 110 : 17492-17497, 2013
 
23) Antonarakis ES, Lu C, Wang H et al : AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 371 : 1028-1038, 2014
PubMed
24) Montgomery RB, Mostaghel EA, Vessella R et al : Maintenance of intratumoral androgens in metastatic prostate cancer : a mechanism for castration-resistant tumor growth. Cancer Res 68 : 4447-4454, 2008
PubMed
25) Ferraldeschi R, Sharifi N, Auchus RJ et al : Molecular pathways : Inhibiting steroid biosynthesis in prostate cancer. Clin Cancer Res 19 : 3353-3359, 2013
 
26) Stanbrough M, Bubley GJ, Ross K et al : Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 66 : 2815-2825, 2006
PubMed
27) Uemura M, Tamura K, Chung S et al : Novel 5 α-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancer. Cancer Sci 99 : 81-86, 2008
 
28) Chang KH. Li R, Papari-Zareei M et al : Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. Proc Natl Acad Sci U S A 108 : 13728-13733, 2011
PubMed
29) Xu J, Wu RC, O'Malley BW : Normal and cancerrelated functions of the p160 steroid receptor coactivator (SRC) family. Nat Rev Cancer 9 : 615-630, 2009
PubMed
30) Tien JC, Liu Z, Liao L et al : The steroid receptor coactivator-3 is required for the development of castration-resistant prostate cancer. Cancer Res 73 : 3997-4008, 2013
PubMed
31) Imamura Y, Sakamoto S, Endo T et al : FOXA1 promotes tumor progresslon m prostate cancer vla the insulin-like growth factor binding protein 3 pathway. PLoS One 7 : e42456, 2012
 
32) Grasso CS, Wu YM, Robinson DR et al : The mutational landscape of lethal castration-resistant prostate cancer. Nature 487 : 239-243, 2012
PubMed
33) Ueda T, Mawji NR, Bruchovsky N et al : Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells. J Biol Chem 277 : 38087-38094, 2002
 
34) Akakura K, Suzuki H, Ueda T et al : Possible mechanism of dexamethasone therapy for prostate cancer : suppression of circulating level of interleukin-6. Prostate 56 : 106-109, 2003
PubMed
35) Tomlills SA, Rhodes DR, Perner S et al : Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310 : 644-648, 2005
 
36) Berg KD, Vainer B, Thomsen FB et al : ERG protein expression in diagnostic specimens is associated with increased risk of progression during active surveillance for prostate cancer. Eur Urol, 2014 [Epub ahead of print]
 
37) Leyten GH, Hessels D, Jannink SA et al : Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur Urol 65 : 534-542, 2014
PubMed
38) Magi-Galluzzi C, Tsusuki T, Elson P et al : TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients. Prostate 71 : 489-497, 2011
PubMed
39) Miyagi Y, Sasaki T, Fujinami K et al : ETS familyassociated gene fusions in Japanese prostate cancer : analysis of 194 radical prostatectomy samples. Mod Pathol 23 : 1492-1498, 2010
PubMed
40) Tomlins SA, Laxman B, Varambally S et al : Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 10 : 177-188, 2008
PubMed
41) Gupta S, Iljin K, Sara H et al : FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res 70 : 6735-6745, 2010
PubMed
42) Kim J, Wu L, Zhao JC et al : TMPRSS2-ERG gene fusions induce prostate tumorigenesis by modulating microRNA miR-200c. Oncogene 33 : 5183-5192, 2014
PubMed
43) Carthew RW, Sontheimer EJ : Origins and Mechanisms of miRNAs and siRNAs. Cell 136 : 642-655, 2009
PubMed
44) Filipowicz W, Bhattacharyya SN, Sonenberg N : Mechanisms of post-transcriptional regulation by microRNAs : are the answers in sight? Nat Rev Genet 9 : 102-114, 2008
PubMed
45) Esquela-Kerscher A, Slack FJ : Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 6 : 259-269, 2006
PubMed
46) Goto Y, Nishikawa R, Kojima S et al : Tumour-suppressive microRNA-224 inhibits cancer cell migration and invasion via targeting oncogenic TPD52 in prostate cancer. FEBS Lett 588 : 1973-1982, 2014
PubMed
47) Kojima S, Enokida H, Yoshino H et al : The tumor-suppressive microRNA-143/145 cluster inhibits cell migration and invasion by targeting GOLM1 in prostate cancer. J Hum Genet 59 : 78-87, 2014
PubMed
48) Fang YX, Gao WQ : Roles of microRNAs during prostatic tumorigenesis and tumor progression. Oncogene 33 : 135-147, 2014
PubMed
49) Thieu W, Tilki D, deVere White RW et al : The role of microRNA in castration-resistant prostate cancer. Urol Oncol 32 : 517-523, 2014
 
50) Kojima S, Chiyomari T, Kawakami K et al : Tumour suppressors miR-1 and miR-133a target the oncogenic function of purine nucleoside phosphorylase (PNP) in prostate cancer. Br J Cancer 106 : 405-413, 2012
 
51) Goto Y, Kojima S, Nishikawa R et al : The microRNA-23b/27b/24-1 cluster is a disease progression marker and tumor suppressor in prostate cancer, Oncotarget 5 : 7748-7759, 2014
PubMed
52) Mitchell PS, Parkin RK, Kroh EM et al : Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 105 : 10513-10518, 2008
PubMed
53) Selth LA, Townley SL, Bert AG et al : Circulating microRNAs predict biochemical recurrence in prostate cancer patients. Br J Cancer 109 : 641-650, 2013
PubMed
54) Huang X, Yuan T, Liang M et al : Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer. Eur Urol 67 : 33-41, 2015
 
55) Martens-Uzunova ES, B6ttcher R, Croce CM et al : Long noncoding RNA in prostate, bladder, and kidney cancer. Eur Urol 65 : 1140-1151, 2014
 

PART 2 CRPC治療薬のプロファイルを整理する !

P.38 掲載の参考文献
1) Tannock IF, de Wit R, Berry WR et al : Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 : 1502-1512, 2004
 
2) Naito S, Tsukamoto T, Koga H et al : Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer : a multicenter Phase II trial in Japan. Jpn J Clin Oncol 38 : 365-372, 2008
 
3) Montero A, Fossella F, Hortobagyi G et al : Docetaxel for treatment of solid tumours : a systematic review of clinical data. Lancet Oncol 6 : 229-239, 2005
PubMed
4) van Soest RJ, van Royen ME, de Morree ES et al : Cross. resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer. Eur J Cancer 49 : 3821-3830, 2013
PubMed
5) Petrylak DP, Tangen CM, Hussain MH et al : Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 : 1513-1520, 2004
PubMed
6) Mera T, Saijo N, Akaza H : [Safety and emcacy of docetaxel in prostate cancer patients : based on the post-marketing surveillance in Japan]. Gan To Kagaku Ryoho 39 : 551-562, 2012
PubMed
7) Semb KA, Aamdal S, Oian P : Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment. J Clin Oncol 16 : 3426-3432, 1998
PubMed
8) Berthold DR, Pond GR, Soban F et al : Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer : updated survival in the TAX 327 study. J Clin Oncol 26 : 242-245, 2008
PubMed
9) Machiels Jp, Mazzeo F, Clausse M et al : Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormonerefractory prostate callcer. J Clin Oncol 26 : 5261-5268, 2008
PubMed
10) Armstrong AJ, Garrett-Mayer E, Ou Yang YC et al : Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol 25 : 3965-3970, 2007
PubMed
11) Armstrong AJ, Garrett-Mayer ES, Yang YC et al : A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer : a TAX327 study analysis. Clin Cancer Res 13 : 6396-6403, 2007
PubMed
12) Armstrong AJ, Tannock IF, de Wit R et al : The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. Eur J Cancer 46 : 517-525, 2010
PubMed
13) Ide H, Kikuchi E, Kono H et al : Docetaxel in combination with prednisolone for hormone refractory prostate cancer. Jpn J Clin Oncol 40 : 79-84, 2010
PubMed
14) Matsuyama H, Shimabukuro T, Hara I et al : Combination of hemoglobin, alkaline phosphatase, and age predicts optimal docetaxel regimen for patients with castration-resistant prostate cancer. Int J Clin Oncol 19 : 946-954, 2014
 
15) Miyake H, Sakai I, Terakawa T et al : Oncological outcome of docetaxel-based chemotherapy for Japanese men with metastatic castration-resistant prostate cancer. Urol Oncol 31 : 733-738, 2013
PubMed
16) Shimabukuro T, Sakano S, Matsuda K et al : Can docetaxel therapy improve overall survival from primary therapy compared with androgen-deprivation therapy alone in Japanese patients with castration-resistant prostate cancer? A multi-institutional cooperative study. Int J Clin Oncol 18 : 62-67, 2013
PubMed
17) Armstrong AJ, Garrett-Mayer E, de Wit R et al : Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer. Clin Cancer Res 16 : 203-211, 2010
PubMed
18) Nishimura K, Nonomura N, Hashine K et al : Prolonged treatment with three-weekly docetaxel plus daily prednisolone for metastatic castration. resistant prostate cancer : a multicenter, phase II. open-label, non-comparative, extension study in Japan. Int J Clin Oncol 18 : 306-313, 2013
PubMed
19) Li YF, Zhang SF, Zhang TT et al : Intermittent triweekly docetaxel plus bicalutamide in patients with castration-resistant prostate cancer : a singlearm prospective study using a historical control for comparison. Asian J Androl 15 : 773-779, 2013
PubMed
20) Mountzios I, Bournakis E, Efstathiou E et al : Intermittent docetaxel chemotherapy in patients with castrate-resistant prostate cancer. Urology 77 : 682-687, 2011
PubMed
21) Narita S, Tsuchiya N, Yuasa T et al : Outcome, clinical prognostic factors and genetic predictors of adverse reactions of intermittent combination chemotherapy with docetaxel, estramustine phosphate and carboplatin for castration-resistant prostate cancer. Int J Clin Oncol 17 : 204-211, 2012
PubMed
22) Soga N, Kato M, Nishikawa K et al : Intermittent docetaxel therapy with estramustine for hormonerefractory prostate cancer in Japanese patients. Int J Clin Oncol 14 : 130-135, 2009
PubMed
23) Sella A, Sternberg CN, Skoneczna I et al : Prostatespecific antigen flare phenomenon with docetaxelbased chemotherapy in patients with androgenindependent prostate cancer. BJU Int 102 : 1607-1609, 2008
PubMed
24) Nelius T, Filleur S : PSA surge/flare-up in patients with castration-refractory prostate cancer during the initial phase of chemotherapy. Prostate 69 : 1802-1807, 2009
PubMed
25) Shigeta K, Kosaka T, Yazawa S et al : Predictive factors for severe and febrile neutropenia during docetaxel chemotherapy for castration-resistant prostate cancer. Int J Clin Oncol, 2014 [Epub ahead of print]
 
26) Italiano A, Ortholan C, Oudard S et al : Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer. Eur Urol 55 : 1368-1375, 2009
PubMed
27) Mukai H, Takahashi S, Nozawa M et al : Phase I dose-escalation and pharmacokinetic study (TED 11576) of cabazitaxel in Japanese patients with castration-resistant prostate cancer. Cancer Chemother Pharmacol 73 : 703-710, 2014
PubMed
P.48 掲載の参考文献
1) Potter GA, Barrie SE, Jarman M et al : Novel steroidal inhibitors of human cytochrome P45017 α (17α-hydroxylase-C17, 20-lyase) : potential agents for the treatment of prostatic cancer. J Med Chem 38 : 2463-2471, 1995
 
2) 医薬品インタビューフォーム. ザイティガ(R)錠250mg (http://www.info.pmda.go.jp/go/pack/4291033FlO24_1_01/)
 
3) de Bono JS, Logothetis CJ, Molina A et al : Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364 : 1995-2005, 2011
PubMed
4) Fizazi K, Scher HI, Molina A et al, COU-AA-301 Investigators : Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer : final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 13 : 983-992, 2012
PubMed
5) Ryan CJ, Smith MR, de Bono JS et al, COU-AA-302 Investigators : Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368 : 138-148, 2013
PubMed
6) Rathkopf DE, Smith MR, de Bono JS et al : Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302). Eur Urol, 2014 [Epub ahead of print]
 
7) Suzuki Y, Nawata H, Soen S et al : Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research : 2014 update. J Bone Miner Metab 32 : 337-350, 2014
PubMed
8) Nelson PS : Molecular states underlying androgen receptor activation : a framework for therapeutics targeting androgen signaling in prostate cancer. J Clin Oncol 30 : 644646, 2012
PubMed
9) 松山豪泰 : 去勢抵抗性前立腺癌に対する個別化治療の可能性. Pharma Medica 32 : 29-33, 2014
Medical*Online
P.57 掲載の参考文献
1) Tran C, Ouk S, Clegg NJ et al : Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324 : 787-790, 2009
PubMed
2) Scher HI, Fizazi K, Saad F et al : Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367 : 1187-1197, 2012
PubMed
3) Beer TM, Armstrong AJ, Rathkopf DE et al : Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371 : 424-433, 2014
PubMed
4) Rathkopf D, Scher HI : Androgen receptor antagonists in castration-resistant prostate cancer. Cancer J 19 : 43-49, 2013
 
5) Cookson MS, Roth BJ, Dahm P et al : Castrationresistant prostate cancer : AUA guideline. (https://www.auanet.org/education/guidelines/castration-resistant-prostate-cancer.cfm)
 
6) Heidenreich A, Bastian PJ, Bellmunt J et al : Guidelines on prostate cancer. (http://www.uroweb.org/guidelines/online-guidelines/)
 
P.64 掲載の参考文献
1) Takeda M, Mizokami A, Mamiya K et al : The establishment of two paclitaxeLresistant prostate cancer cel川ines and the mechanisms of paclitaxel resistance with two cell lines. Prostate 67 : 955-967, 2007
 
2) Vrignaud P, S6miond D, Lejeune P et al : Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors. Clin Cancer Res 19 : 2973-2983, 2013
 
3) Mita AC, Denis LJ, Rowinsky EK et al : Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hourinfusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 15 : 723-730, 2009
 
4) Pivot X, Koralewski P, Hidalgo JL et al : A multicenter phase II study of XRP6258 administered as a 1-h i. v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol 19 : 1547-1552, 2008
 
5) Saeki T, Nomizu T, Toi M et al : Dofequidar fumarate (MS-209) in combination with cyclophosphamide, doxorubicin, and fluorouracil for patients with advanced or recurrent breast cancer. J Clin Oncol 25 : 411-417, 2007
PubMed
6) Schinkel AH, Smit JJ, van Tellingen O et al : Disruption of the mouse mdrla P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77 : 491-502, 1994
 
7) Girard E, Ditzler S, Lee D et al : Efficacy of cabazitaxel in mouse models of pediatric brain tumors. Neuro Oncol, 2014 [Epub ahead of print]
 
8) De Placido S, Rescigno P, Federico P et al : Cabazitaxel in castration resistant prostate cancer with brain metastases : 3 case reports. World J Clin Cases 2 : 228-231, 2014
PubMed
9) de Bono JS, Oudard S, Ozguroglu M et al : Prednisone plus cabazitaxel or mitoxantrone for metastatlc castratlon-reslstant prostate cancer progressing after docetaxel treatment : a randomised open-label trial. Lancet 376 : 1147-1154, 2010
PubMed
10) Bahl A, Oudard S, Tombal B et al : Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. Ann Oncol 24 : 2402-2408, 2013
PubMed
11) Mukai H, Takahashi S, Nozawa M et al : Phase I dose-escalation and pharmacokinetic study (TED 11576) of cabazitaxel in Japanese patients with castration-resistant prostate cancer. Cancer Chemother Pharmacol 73 : 703-710, 2014
PubMed
12) Takahashi S et al : Phase I Clinical study of cabazitaxel plus predonisolone for the treatment of metastatlc Castratlon-reslstant prostate cancer (mCRPC) in a Japanese population. ASCO GU #237, 2014
 
13) Naito S, Tsukamoto T, Koga H et al : Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer : a multicenter Phase II trial in Japan. Jpn J Clin Oncol 38 : 365-372, 2008
 
14) de Bono JS, Logothetis CJ, Molina A et al : Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364 : 1995-2005, 2011
PubMed
15) Scher HI, Fizazi K. Saad F et al : Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367 : 1187-1197, 2012
PubMed
16) Loriot Y. Bianchini D, Ileana E et al : Antitumour activity of abiraterone acetate against metastatic castratlon-reslstant prostate cancer Progresslng after docetaxel and enzalutamide (MDV3100). Ann Oncol 24 : 1807-1812, 2013
PubMed
17) Bianchini D, Lorente D, Rodriguez-Vida A et al : Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone. Eur J Cancer 50 : 78-84. 2014
PubMed
18) Pezaro CJ, Omlin AG, Altavilla A et al : Activity of cabazitaxel in castration-resistant Prostate cancer progressing after docetaxel and next-generation endocrine agents. Eur Urol 66 : 459-465, 2014
PubMed
19) Al Nakouzi N. Le Moulec S, Albiges L et al : Cabazitaxel remains active in patients progressing after docetaxcl followed by novel androgen receptor pathway targeted therapies. Eur Urol. 2014 [Epub ahead of print]
 
20) Smith TJ, Khatcheressian J, Lyman GH et al : 2006 update of recommendations for the use of white blood cell growth factors : an evidence-based clinical practice guideline. J Clin Oncol 24 : 3187-3205, 2006
PubMed
P.68 掲載の参考文献
1) Ryan CJ et al : N Engl J Med 368 : 138-148, 2013
PubMed
2) Beer TM et al : N Engl J Med 371 : 424-433, 2014
PubMed
3) Tannock IF et al : N Engl J Med 351 : 1502-1512, 2004
PubMed
4) de Bono JS et al : Lancet 376 : 1147-1154, 2010
PubMed
5) Fizazi K et al : Lancet Oncol 13 : 983-992, 2012
PubMed
6) Scher HI et al : N Engl J Med 367 : 1187-1197, 2012
PubMed
7) Matsubara N et al : Jpn J Clin Oncol 44 : 1216-1226, 2014
PubMed
8) Naito S et al ; Jpn J Clin Oncol 38 : 365-372, 2008
PubMed
9) Satoh T et al : Jpn J Clin Oncol 44 : 1206-1215, 2014
PubMed
10) イクスタンジ(R) 医薬品インタビューフォーム, 2014
 
11) ジェブタナ(R) 医薬品インタビューフォーム, 2014
 

PART 3 CRPC治療薬はこう使う ! - 適応となる患者像と処方の実際 -

P.75 掲載の参考文献
1) Tannock IF, de Wit R, Berry WR et al : Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 : 1502-1512, 2004
 
2) Petrylak DP, Tangen CM, Hussain MH et al : Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 : 1513-1520, 2004
PubMed
3) Armstrong AJ, Tannock IF, de Wit R et al : The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. Eur J Cancer 46 : 517-525, 2010
PubMed
4) Miyake H, Sakai I, Terakawa T et al : Oncological outcome of docetaxel-based chemotherapy for Japanese men with metastatic castration-resistant prostate cancer. Urol Oncol 31 : 733-738, 2013
PubMed
5) Naito S, Tsukamoto T, Koga H et al : Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer : a multicenter Phase II trial in Japan. Jpn J Clin Oncol 38 : 365-372, 2008
 
6) Sella A, Sternberg CN, Skoneczna I et al : Prostatespecific antigen flare phenolnenon with docetaxelbased chemotherapy in patients with androgen-independent prostate cancer. BJU Int 102 : 1607-1609, 2008
PubMed
7) Dennis ER, Jia X, Mezheritskiy IS et al : Bone scan index : a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer. J Clin Oncol 30 : 519-524, 2012
PubMed
P.84 掲載の参考文献
1) 前立腺癌取扱い規約第4版, 日本泌尿器科学会・日本病理学会・日本医学放射線学会編, 金原出版, 東京, 2010
 
2) de Bono JS, Logothetis CJ, Molina A et al : Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364 : 1995-2005, 2011
PubMed
3) Fizazi K, Scher HI, Molina A et al : Abiraterone acetate for treatment of metastatic castration. resistant prostate cancer : final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 13 : 983-992, 2012
PubMed
4) Mulders PF, Molina A, Marberger M et al : Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatlc castratlon-resiStant prostate cancer after docetaxel-based chemotherapy. Eur Urol 65 : 875-883, 2014
 
5) Logothetis CJ, Basch E, Molina A et al : Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer : exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol 13 : 1210-1217, 2012.
PubMed
6) Ryan CJ, Smith MR, de Bono JS et al : Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368 : 138-148, 2013
PubMed
7) Rathkopf DE, Smith MR, de Bono JS et al : Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castratlon-reslstant prostate cancer patients without prior chemotherapy (COU-AA-302). Eur Urol, 2014 [Epub ahead of print]
 
8) Guidelines on Prostate Cancer, European Association of Urology, Update April 2014
 
9) NCCN guideline 2014 ver2,
 
10) ザイティガ(R) 錠250mgインタビューフォーム, 2014
 
11) ザイティガ(R) 錠250mg添付文書 (第1版), 2014
 
12) プレドニン錠(R) 添付文書
 
13) Matsubara N, Uemura H, Satoh T et al : A Phase 2 Trial of Abiraterone Acetate in Japanese Men with Metastatic Castration-resistant Prostate Cancer and without Prior Chemotherapy (JPN-201 Study). Jpn J Clin Oncol 44 : 1216-1226, 2014
 
14) Satoh T, Uemura H, Tanabe K et al : A Phase 2 Study of Abiraterone Acetate in Japanese Men with Metastatic Castration. resistant Prostate Cancer Who Had Received Docetaxel-based Chemotherapy. Jpn J Clin Oncol 44 : 1206-1215, 2014
PubMed
P.88 掲載の参考文献
1) Tannock IF, de Wit R, Berry WR et al : Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 : 1502-1512, 2004
 
2) Scher HI, Fizazi K, Saad F et al : Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367 : 1187-1197, 2012
PubMed
3) Beer TM, Armstrong AJ, Rathkopf DE et al : Enzalutamide in Metastatic Prostate Cancer before Chemotherapy. N Engl J Med 371 : 424-433, 2014
PubMed
4) 前立腺癌診療ガイドライン2012年版, 日本泌尿器科学会, 金原出版, 東京, 2012, pp. 188-191
 
5) Suzuki H, Okihara K, Miyake H et al : Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. J Urol 180 : 921-927, 2008
PubMed
6) Miyake H, Hara I, Eto H : Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer. BIU Int 96 : 791-795, 2005
 
7) Schrader AJ, Boegemann M, Ohlmann CH et al : Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone. Eur Urol 65 : 30-36, 2014
PubMed
8) Loriot Y, Bianchini D, Ileana E et al : Antitumour activity of abiraterone acetate against metastatic Castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Ann Oncol 24 : 1807-1812, 2013
PubMed
9) de Bono JS, Logothetis CJ, Molina A et al : Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364 : 1995-2005, 2011
PubMed
P.94 掲載の参考文献
1) Tannock IE de Wit R, Berry WR et al : Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 : 1502-1512, 2004
PubMed
2) de Bono JS, Oudard S, Ozguroglu M et al : Prednisone plus cabazitaxel or mitoxantrone for metastatlc castratlon-reslstant prostate cancer progressing after docetaxel treatment : a randomised open-label trial. Lancet 376 : 1147-1154, 2010
PubMed
3) Sridhar SS, Freedland SJ, Gleave ME et al : Castration-resistant prostate cancer : from new pathophysiology to new treatment. Eur Urol 65 : 289-299, 2014
PubMed
4) Mezynski J, Pezaro C, Bianchini D et al : Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone : clinical evidence for cross-resistance? Ann Oncol 23 : 2943-2947, 2012
PubMed
5) Cisternino S, Bourasset F, Archimbaud Y et al : Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P-glycoprotein at the blood-brain barrier in mice and rats. Br J Pharmacol 138 : 1367-1375, 2003
PubMed
6) De Placido S, Rescigno P, Federico P et al : Cabazitaxel in castration resistant prostate cancer with brain metastases : 3 case reports. World J Clin Cases 2 : 228-231, 2014
PubMed
7) Pezaro CJ, Omlin AG, Altavilla A et al : Activity of cabazitaxel in castration-resistant Prostate cancer progressing after docetaxel and next-generation endocrine agents. Eur Urol 66 : 459-465, 2014
PubMed
8) Al Nakouzi N, Le Moulec S, Albiges L et al : Cabazitaxel remains active in patients progressing after docetaxei followed by novel androgen receptor pathway targeted therapies. Eur Urol, 2014 [Epub ahead of print]
 
9) 上村博司, Tombal BF : 新規治療薬の導入で変わる去勢抵抗性前立腺がん (CRPC) の治療概念. 診療と新薬 51 : 723-729, 2014
 
10) Pouessel D, Oudard S, Gravis G et al : [Cabazitaxel for metastatic castration-resistant prostate cancer progressing after docetaxel treatment : the TROPIC study in France]. Bull Cancer 99 : 731-741, 2012
PubMed
11) Angelergues A, Maillet D, Flechon A et al : Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer. Eur J Cancer 50 : 1602-1609, 2014
PubMed
12) Fitzpatrick JM, Bellmunt J, Fizazi K et al : Optimal management of metastatic castration-resistant prostate cancer : highlights from a European Expert Consensus Panel. Eur J Cancer 50 : 1617-1627, 2014
PubMed

PART 4 想定すべき副作用とは ? 適切な対応とは ?

P.106 掲載の参考文献
1) Tannock IF, de Wit R, Berry WR et al : Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 : 1502-1512, 2014
 
2) Naito S, Tsukamoto T, Koga H et al : Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer : a multicenter Phase II trial in Japan. Jpn J Clin Oncol 38 : 365-372, 2008
 
3) Burris HA : Optimal use of docetaxel (Taxotere) : maximizing its potential. Anti-cancer drugs 7 Suppl 2 : 25-28, 1996
 
4) Scotte F, Tourani JM, Banu E et al : Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand. J Clin Oncol 23 : 4424-4429, 2005
PubMed
5) Hervonen P, Joensuu H, Joensuu T et al : Biweekly docetaxel is better tolerated than conventional three-weekly dosing for advanced hormone-refractory prostate cancer. Anticancer Res 32 : 953-956, 2012
PubMed
6) Italiano A, Ortholan C, Oudard S et al : Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer. Eur Urol 55 : 1368-1375, 2009
PubMed
7) Takaha N, Okihara K, Kamoi K et al : Feasibility of tri-weekly docetaxel-based chemotherapy for elderly patients (age 75 and older) with castration-resistant prostate cancer. Urologia in ternationalis 87 : 263-269, 2011
 
P.112 掲載の参考文献
1) Sonpavde G. Attard G, Bellmunt J et al : The role of abiraterone acetate in the management of prostate cancer : acritical analysis of the literature. Eur Urol 160 : 270-278, 2011
 
2) Matsubara N, Uemura H, Satoh T et al : A phase 2 trial of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer and without prior chemotherapy. Jpn J Clin Oncol 44 : 1216-1226, 2014
 
3) Satoh T, Uemura H, Tanabe K et al : A phase 2 study of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer who had received docetaxel-based chemotherapy. Jpn J Clin Oncol 44 : 1206-1215, 2014
PubMed
4) Ryan CJ, Smith MR, de Bono JS et al : Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368 : 138-148, 2013
PubMed
5) de Bono JS, Logothetis CJ, Molina A et al : Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364 : 1995-2005, 2011
PubMed
6) ザイティガ(R) 適正使用ガイド. 市販直後調査, 2014
 
P.119 掲載の参考文献
1) Scher HI, Fizazi K, Saad F et al : Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367 : 1187-1197, 2012
PubMed
2) Beer TM, Armstrong AJ, Rathkopf D et al : Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371 : 424-433, 2014
PubMed
3) Tran C, Ouk S, Clegg NJ et al : Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324 : 787-790, 2009
PubMed
4) イクスタンジ(R) 医薬品インタビューフォーム, 新医薬品の「使用上の注意」の解説. 2014
 
5) 厚生労働省 : 重篤副作用疾患別対応マニュアル痙攣・てんかん. 2009
 
P.129 掲載の参考文献
1) Mukai H, Takahashi S, Nozawa M et al : Phase I dose-escalation and pharmacokinetic study (TED 11576) of cabazitaxel in Japanese patients with castration-resistant prostate cancer. Cancer Chemother Pharmacol 73 : 703-710, 2014
PubMed
2) de Bono JS. Oudard S. Ozguroglu M et al : Prednisone plus cabazitaxel or mitoxantrone for metastatlc castratlon-reslstant prostate cancer progressing after docetaxel treatment : a randomised open-label trial. Lancet 376 : 1147-1154, 2010
PubMed
3) Schutz FA. Buzaid AC, Sartor O : Taxanes in the management of metastatic castration-resistant prostate cancer : efficacy and management of toxicity. Crit Rev Oncol Hematol 91 : 248-256, 2014
PubMed
4) ジェブタナ(R) 適正使用ガイド, 2014年9月作成
 
5) Castells MC, Tennant NM, Sloane DE et al : Hypersensitivity reactions to chemotherapy : 0utcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol 122 : 574-580, 2008
 
6) G-CSF適正使用ガイドライン (2013年版). 日本癌治療学会編, 金原出版, 東京, 2013
 
7) Di Lorenzo G, D'Aniello C, Buonerba C et al : Pegfilgrastim and cabazitaxel in prostate cancer patients. Anticancer Drugs 24 : 84-89, 2013
 
8) Masaoka T : Evidence-based recommendations for antimicrobial use in febrile neutropenia in Japan : executive summary. Clin Infect Dis 39 (Suppl 1) : S49-S52, 2004
 
9) Klastersky J, Paesmans M, Rubenstein EB et al : The Multinational Association for Supportive Care in Cancer risk index : a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18 : 3038-3051, 2000
PubMed
10）Muehlbauer PM, Thorpe D, Davis A et al : Putting evidence into practice : evidence-based interventions to prevent, manage, and treat chemotherapy-and radiotherapy-induced diarrhea. Clin J Oncol Nurs 13 : 336-341, 2009
PubMed

PART 5 CRPCの臨床マネジメントの展望と今後の可能性

P.140 掲載の参考文献
1) Tannock IE de Wit R, Berry WR et al : Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 : 1502-1512, 2004
PubMed
2) de Bono JS, Logothetis CJ, Molina A et al : Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364 : 1995-2005, 2011
PubMed
3) Scher HI, Fizazi K, Saad F et al : Increased survival with enzalutamide in prostate cancer after chemotherapy. N Eng〃Med 367 : 1187-1197, 2012
 
4) de Bono JS, Oudard S, Ozguroglu M et al : Prednisone plus cabazitaxel or mitoxantrone for metastatlc castratlon-reslstant prostate cancer progressing after docetaxel treatment : a randomised open-label trial. Lancet 376 : 1147-1154, 2010
PubMed
5) American Urological Association : Castration. Resistant Prostate Cancer : AUA Guideline. 2014 (http://www.auanetorg/education/aua-guidelines.cfm)
 
6) Akakura K Akimoto S, Furuya Y et al : Incidence and characteristics of antiandrogen withdrawal syndrome in prostate carlcer after treatment with chlormadinone acetate. Eur Urol 33 : 567-571, 1998
PubMed
7) Kojima S, Suzuki H, Akakura K et al : Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy. J Urol 171 : 679-683, 2004
PubMed
8) Ryan CJ, Shah S Efstathiou E et al : Phase II study of abiraterone acctate in chemotherapy-naive metastatlC Castratlon-reslstant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res 17 : 4854-4861, 2011
 
9) Beer TM, Armstrong AJ, Rathkopf DE et al : Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371 : 424-433, 2014
PubMed
10) Saad F, Gleason DM, Murray R et al : Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96 : 879-882, 2004
PubMed
11) Fizazi K, Carducci M, Smith M et al : Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer : a randomised, double-blind study. Lancet 377 : 813-822, 2011
PubMed
12) Parker C, Nilsson S, Heinrich D et al : α emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369 : 213-223, 2013
 
13) Fitzpatrick JM, Bellmunt J, Fizazi K et al : Optimal management of metastatic castration-resistant prostate cancer : highlights from a European Expert Consensus Panel. Eur J Cancer 50 : 1617-1627, 2014
PubMed
14) van Soest RJ, van Royen ME, de Morree ES et al : Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer. Eur J Cancer 49 : 3821-3830, 2013
PubMed
15) Azad AA, Eigl BJ, Murray RN et al : Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients. Eur Urol 67 : 23-29, 2015
PubMed
16) Badrising S, van der Noort V, van Oort IM et al : Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castrationresistant prostate cancer who progress after docetaxel and abiraterone treatment. Cancer 120 : 968-975, 2014
PubMed
17) Schweizer MT, Zhou XC, Wang H et al : The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate callcer. Eur Urol 66 : 646-652, 2014
PubMed
18) Noonan KL, North S, Bitting RL et al : Clinical activity of abiraterone acetate in patients with metastatlc castratlon-reslstant prostate cancer progressing after enzalutamide. Ann Oncol 24 : 1802-1807. 2013
PubMed
19) Mohler JL, Gregory CW, Ford OH 3rd et al : The androgen axis in recurrent prostate cancer. Clin Cancer Res 10 : 440-448, 2004
PubMed
20) Takeda H, Akakura K, Masai M et al : Androgen receptor content of prostate carcinoma cells estimated by immunohistochemistry is related to prognosis of patients with stage D2 prostate carcinoma. Cancer 77 : 934-940, 1996
PubMed
21) Takizawa I, Hara N, Nishiyama T et al : Adrenocorticotropic hormone is involved in regulation of androgen synthesis in men receiving androgen deprivation therapy for localized prostate cancer. J Urol 184 : 1971-1976, 2010
PubMed
22) Ryan CJ, Molina A, Li J et al : Serum androgens as prognostic biomarkers in castration-resistant prostate cancer : results from an analysis of a randomized phase III trial. J Clin Oncol 31 : 2791-2798, 2013
PubMed
23) Lafeuille MH, Gravel J, Grittner A et al : Realworld corticosteroid utilization patterns in patients with metastatic castration-resistant prostate cancer in 2 large US administrative claims databases. Am Health Drug Benefits 6 : 307-316. 2013
PubMed
24) Antonarakis ES, Lu C, Wang H et al : AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 371 : 1028-1038, 2014
PubMed
P.146 掲載の参考文献
1) National Comprehensive Cancer Network : NCCN Guidelines for Senior Adult Oncology Updated. Version 22014 (http://www.nccn.org/professionals/physician_gls/pdf/senior.pdf)
 
2) Kelly WK, Scher HI : Prostate specific antigen decline after antiandrogen withdrawal : the flutamide withdrawal syndrome. J Urol 149 : 607-609, 1993
PubMed
3) Sartor AO, Tangen CM, Hussain MH et al : Antiandrogen withdrawal in castrate-refractory prostate cancer : a Southwest Oncology Group trial (SWOG 9426). Cancer 112 : 2293-2400, 2008
 
4) Suzuki H, Okihara K, Miyake H et al : Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. J Urol 180 : 921-927, 2008
PubMed
5) Petrylak DP, Tangen CM, Hussain MH et al : Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 : 1513-1520, 2004
PubMed
6) Tannock IE de Wit R, Berry WR et al : Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 : 1502-1512, 2004
PubMed
7) Berry W, Dakhil S, Modiano M et al : Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with a symptomatic hormone refractory prostate cancer. J Urol 168 : 2439-2443, 2002
 
8) Berthold DR, Pond GR, Soban F et al : Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer : updated survival in the TAX 327 study. J Clin Oncol 26 : 242-245, 2008
PubMed
9) Berthold DR, Pond GR, Roessner M et al : Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone : relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study. Clin Cancer Res 14 : 2763-2767, 2008
PubMed
10) 前立腺癌診療ガイドライン2012年版, 日本泌尿器科学会編, 金原出版, 東京, 2012
 
11) Berry W, Dakhil S, Gregurich MA et al : Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. Semin Oncol 28 (4 Suppl 15) : 8-15, 2001
 
12) Beer TM, Pierce WC, Lowe BA et al : Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. Ann Oncol 12 : 1273-1279, 2001
PubMed
13) Horgan AM, Seruga B. Pond GR et al : Tolerability and efficacy of docetaxel in older men with metastatlc castrate-reslstant prostate cancer (mCRPC) in the TAX 327 trial. J Geriatr Oncol 5 : 119-126, 2014
 
14) Oudard S, Banu E, Beuzeboc P et al : Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate Caner. J Clin Oncol 23 : 3343-3351, 2005
 
15) Fossa SD, Jacobsen AB, Ginman C et al : Weekly docetaxel and prednisolone versus prednisolone alone in androgen-independent prostate cancer : A randomized phase II study. Eur Urol 52 : 1691-1698, 2007
PubMed
16) Kellokumpu-Lehtinen PL, Harmenberg U et al : 2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer : a randomised, phase 3 trial. Lancet Oncol 14 : 117-124, 2013
PubMed
17) Kellokumpu-Lehtinen PL, Harmenberg U, Hervonen P et al : Triweekly docetaxel versus biweekly docetaxel as a treatment for advanced castration resistant prostate cancer : Quality of life analysis. J Clin Oncol 32 (suppl 4) : 23, 2014
 
18) Nakai Y, Nishimura K, Nakayama M et al : Weekly, low-dose docetaxel combined with estramustine for Japanese castration-resistant prostate cancer : its efficacy and safety profile compared with tri-weekly standard-dose treatment. Int J Clin Oncol 19 : 165-172, 2014
 
19) Suzuki Y, Nawata H, Soen S et al : Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research : 2014 update. J Bone Miner Metab 32 : 337-350, 2014
PubMed
P.151 掲載の参考文献
1) Saad F, Gleason DM, Murray R et al : A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94 : 1458-1468, 2002
 
2) Saad F, Gleason DM, Murray R et al : Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96 : 879-882, 2004
PubMed
3) Smith MR, Egerdie B, HernAndez Toriz N et al : Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 361 : 745-755, 2009
PubMed
4) Fizazi K, Carducci M, Smith M et al : Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer : a randomised, double-blind study. Lancet 377 : 813-822, 2011
PubMed
5) Smith MR, Halabi S, Ryan CJ et al : Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases : results of CALGB 90202 (alliance). J Clin Oncol 32 : 1143-1150, 2014
 
6) Shahinian VB, Kuo YF, Freeman JL et al : Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352 : 154-164, 2005
PubMed
7) Michaelson MD, Kaufman DS, Lee H et al : Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 25 : 1038-1042, 2007
PubMed
8) Suzuki Y, Nawata H, Soen S et al : Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Socicty for Bone and Mineral Research : 2014 update. J Bone Miner Metab 32 : 337-350, 2014
PubMed
9) Gardner JR, Livingston PM, Fraser SF : Effects of exercise on treatment-related adverse effects for patients with prostate cancer receiving androgen-deprivation therapy : a systematic review. J Clin Oncol 32 : 335-346, 2014
PubMed
P.157 掲載の参考文献
1) de Bono JS, Logothetis CJ, Molina A et al : Abiraterone and increased survival in metastatic prostate cancer. COU-AA-301 Investigators. N Engl J Med 364 : 1995-2005, 2011
 
2) Scher HI, Fizazi K, Saad F et al : Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367 : 1187-1197, 2012
PubMed
3) de Bono JS, Oudard S, Ozguroglu M et al : Prednisone plus cabazitaxel or mitoxantrone for metastatlc castratlon-reslstant prostate cancer progressing after docetaxel treatment : a randomised open-label trial. Lancet 376 : 1147-1154, 2010
PubMed
4) Scher HI, Halabi S, Tannock I et al : Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone : recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26 : 1148-1159, 2008
 
5) http://www.uroweb.org/gls/pdf/09_Prostate_Carlcer_LR.pdf#search=EAU+guidelines+2013+prostate+cancer
 
6) http://www.uroweb.org/gls/pdf/1607%20Prostate%20Cancer_LRV3.pdf
 
7) 前立腺癌診療ガイドライン2012年版 (第2版), 日本泌尿器科学会, 金原出版, 東京, 2012
 
8) Tombal B, Borre M, Rathenborg P et al : Enzalutamide monotherapy in hormone-naive prostate cancer : primary analysis of an open-label, single-arm, phase 2 study. Lancet Oncol 15 : 592-600, 2014
PubMed
9) Attard G, Sydes MR, Mason MD et al : Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial. Eur Urol, 2014 [Epub ahead of print]
 
10) Gravis G, Fizazi K, Joly F et al : Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15) : a randomised, open-label, phase 3 trial. Lancet Oncol 14 : 149-158, 2013
 
11) http://am.asco.org/adding-chemotherapy-hormone-therapy-improved-survival-men-newly-metastatic-prostate.cancer (Sweeney C et al, ASCO2014)
 
P.163 掲載の参考文献
1) Klotz, LH, Goldenberg SL, Jewett M et al : CUOG randomized trial of neoadjuvant androgen ablation before radical prostatectomy : 36-month post treatment PSA results. Canadian Urologic Oncology Group. Urology 53 : 757-763, 1999
PubMed
2) Soloway MS, Pareek K, Sharifi R et al : Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer : Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy : biochemical and pathological effects. J Urol 166 : 500-506, 2001
 
4) Thalgott M, Horn T, Heck MM et al : Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer. J Hematol Oncol, 2014 [Epub ahead of print]
 
5) Silberstein JL, Poon SA, Sjoberg DD et al : Long term oncologic outcomes of a Phase II trial of neoadjuvant chemohormonal therapy followed by radical prostatectomy for patients with clinically localized, high-risk prostate cancer. BJU Int, 2014 [Epub ahead of print]
 
6) Fizazi K, Lesaunier F, Delva R et al : A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer : a planned analysis of response, toxicity and quality of life in the GETUG 12 trial. Eur J Cancer 48 : 209-217, 2012
PubMed
7) Eastham JA, Kelly WK, Grossfeld GD et al : Cancer and Leukemia Group B (CALGB) 90203 : a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease. Urology 62 Suppl 1 : 55-62, 2003
 
8) Bolla M, Collette L, Blank L et al : Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study) : a phase III randomised trial. Lancet 360 : 103-106, 2002
PubMed
9) Horwitz EM, Bae K, Hanks GE et al : Ten-year follow-up of radiation therapy oncology group protocol 92-02 : a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 26 : 2497-2504, 2008
PubMed
10) Bria E, Cuppone F, Giannarelli D et al : Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer? : meta-analysis of randomized trials. Cancer 115: 3446-3456, 2009
PubMed
11) Yamanaka H, Ito K, Naito S et al : Effectiveness of adjuvant intermittent endocrine therapy following neoadjuvant endocrine therapy and external beam radiation therapy in men with locally advanced prostate cancer. Prostate 63 : 56-64, 2005
PubMed
12) Bolla M, van Poppel H, Collette L et al : Postoperative radiotherapy after radical prostatectomy : a randomised controlled trial (EORTC trial 22911). Lancet 366 : 572-578, 2005
PubMed
13) Sweeney C, Chen YH, Carducci MA et al : Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa) : An ECOG-led phase III randomized trial. J Clin Oncol 32 : 5s, 2014 (suppl ; abstr LBA2)
 
14) Gravis G, Fizazi K, Joly F et al : Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15) : a randomised, open-label, phase 3 trial. Lancet Oncol 14 : 149-158, 2013
 
15) Smith MR, Halabi S, Ryan CJ et al : Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases : results of CALGB 90202 (alliance). J Clin Oncol 32 : 1143-1150, 2014
 
16) Ogawa O et al : A phase III, multicenter, randomized, controlled study of maximum androgen blockade with vs. without zoledronic acid in prostatic cancer patients with metastatic bone disease. (http://clinicaltrials.gov/ct2/show/NCT00685646)
 
17) Wirth M, Tammela T, Cicalese V et al : Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid : efficacy and safety results of the zometa european study (ZEUS). Eur Urol, 2014 [Epub ahead of print]
 
P.169 掲載の参考文献
1) Coleman RE : Metastatic bone disease : clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27 : 165-176, 2001
PubMed
2) Fitton A, McTavish D : Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 41 : 289-318, 1991
PubMed
3) Green JR, Muller K, Jaeggi KA : Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 9 : 745-751, 1994
 
4) Saad F, Gleason DM, Murray R et al : Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96 : 879-882, 2004
PubMed
5) Rosen LS, Gordon D, Tchekmedyian NS et al : Long-term eihcacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other soild tumors : a randomized, Phase III, double-blind, placebo-controlled trial. Cancer 100 : 2613-2621, 2004
 
6) ゾレドロン酸のEBM, 尾形悦郎監修, メディカルレビュー社, 東京, 2006
 
7) 絹谷清剛 : アイソトープ内用療法の現状と将来のために考えるべきこと. Isotope News No. 698 : 2-6, 2012
 
8) Parker C, Nilsson S, Heinrich D et al : α emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369 : 213-223, 2013
 
9) Smith DC, Smith MR, Sweeney C et al : Cabozantinib in patients with advanced prostate cancer : results of a phase II randomized discontinuation trial. J Clin Oncol 31 : 412-419, 2013
 
10) Lee RJ, Saylor PJ, Michaelson MD et al : A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases. Clin Cancer Res 19 : 3088-3094, 2013
 
11) Smith MR, Sweeney CJ, Corn PG et al : Cabozantinib in chemotherapy-pretreated metastaUc castratlon-reslstant prostate cancer : results of a phase II nonrandomized expansion study. J Clin Oncol 32 : 3391-3399, 2014
PubMed

書評

最近チェックした商品履歴

Loading...